{
  "docId": "019de071-4ec1-761e-bce7-779cb9a1fe78",
  "docSlug": "bd64755c9d094dce862ec77cfb2b1978",
  "documentTitle": "TScan Therapeutics | IPO Presentation Deck | 43 slides",
  "authorId": "tscan-therapeutics",
  "authorName": "TScan Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 43,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style visualization to show the current development stage of multiple drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4ec1-761e-bce7-779cb9a1fe78/9",
  "deckHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78",
  "deckJsonHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78.json",
  "deckAnchorHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Pipeline development status for TSC-100, TSC-101, TSC-200, TSC-201, TSC-202, TSC-203",
      "attrs": null,
      "subkind": "gantt-chart",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbe8cfa0-d059-44a6-af8b-31767df63fa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: The TSC-200 product series is designed to be used in combination as part of a multiplexed TCR-T therapy, with treatment tailored to target expression in each patient tumor. 1 TSC-200 will only be developed in HPV-positive cancers, which include head & neck, cervical, and anal cancers. 2 AML: Acute myeloid leukemia; MDS: Myelodysplastic syndromes; ALL: Acute lymphocytic leukemia. 3 NSCLC: Non-small cell lung cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24471d7a-425f-4440-8856-349d4e65f961",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Proprietary TCR-T pipeline addresses liquid and solid tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "589e657d-7ff4-40e7-9705-aa0ab6268b20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "e8d8d31a-a7cd-4779-a2aa-ca3e58498021",
      "evidence": "Visual representation of project timelines and development stages.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "b1431f82-1cfa-496e-bf51-8dcfe1b966ab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a comprehensive overview of TScan Therapeutics' solution, including its proprietary TCR-T pipeline and TargetScan platform.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "af0b626c-c83f-46d7-8946-9b828a4fc0e6",
      "evidence": "The document presents a comprehensive overview of TScan Therapeutics' solution, including its proprietary TCR-T pipeline and TargetScan platform.",
      "position": 1,
      "objective": "Why is TScan Therapeutics' multiplexed TCR-T therapy a good solution for patients with cancer?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}